Reduced Volume of Inspiratory Resistance Training

Hypertension Clinical Trial

— REVIRT  

Official title:

Maintenance Dose of Inspiratory Muscle Strength Training to Preserve Cardiovascular Adaptations

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05744817
• Other study ID #: 00002581
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 15, 2024
• Est. completion date: March 2025

Study information

• Verified date: May 2024
• Source: University of Arizona
• Contact: Dallin Tavoian, PhD
• Phone: 5206210388
• Email: tavoian[@]arizona.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical research study will investigate the dose of inspiratory muscle strength training needed to maintain cardiovascular adaptations induced by a six-week loading dose.

Description:

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide. Although it is well-known that lifestyle changes (e.g., diet, exercise) lower blood pressure (BP) and risk for cardiovascular events, an estimated ~98% of US adults with above-normal BP do not adhere to the recommended lifestyle behaviors. Common barriers to exercise, including lethargy, low exercise self-efficacy, fear of exercise-related pain, and lack of time, make adherence to traditional exercise strategies particularly difficult. The need for novel/different forms of exercise that are i) time-efficient, ii) well-tolerated, and iii) effective has never been greater.

Inspiratory muscle strength training (IMST) is a novel, time-efficient respiratory exercise, comprising just 5 sets of 6 inspiratory efforts with 1-minute rests between sets. This training takes just 5 mins/day, 5 sessions/wk, for a total weekly training time of 25-30 minutes. Distinct from other forms of traditional aerobic or high-intensity interval-type exercise, IMST is performed on a hand-held device in sitting or standing. Participants make repeated inspiratory efforts against a resistance and generate large negative pressures that are 2-4-fold greater than those generated during rest breathing, deep breathing, or high-intensity aerobic exercise. The investigators have shown that IMST performed 5 days/wk for 6 weeks, lowers SBP 9 ± 1 mmHg on average.

It is well known that exercise-induced adaptations plateau over time, despite increases in volume and/or intensity. Accordingly, the goal of exercise is not only to improve health, but to maintain health adaptations long term. Importantly, the dose of exercise required to improve health/performance is higher than the dose required to maintain health/performance. Given that lack of time is the most often cited reason for adults failing to initiate exercise and stopping chronic exercise participation, it is essential that any potential participant 1) appreciate the relationship between time spent exercising and health improvements and 2) understand how much exercise is needed to preserve exercise-induced adaptations to ensure an unnecessary amount of time is devoted to exercise. The investigators have shown that 6 weeks of IMST can significantly lower BP and improve respiratory strength, however, the dose needed to preserve these adaptations is unknown.

This study comprises a 6-week loading dose of IMST (5 days/week; Endpoint 1), followed by 12 weeks of IMST at a reduced dose (0, 1, or 3 days/week; Endpoint 2).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 36
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• 50+ years of age

• systolic blood pressure between 120-169 mmHg

• stable dose of medication (three months on the same dose)

• weight stable in the prior 3 months (<3.0 kg weight change) and willing to remain weight stable throughout the study

• absence of unstable clinical disease as determined by medical history

• owns a smartphone

Exclusion Criteria:

• current smoker (including tobacco products, vaping devices, THC, etc…)

• have an uncontrolled medical condition (e.g., cancer)

• myocardial infarction or stroke within the previous 12 months

• performs regular aerobic exercise (>4 bouts/week)

• BMI = 40 kg/m2

• systolic blood pressure <120 or =170 mmHg

• diastolic blood pressure >100 or <60 mmHg

• Cheyne-Stokes respiration

• history of perforated eardrum

• history of glaucoma or retinopathy

• history of collapsed lung

• diagnosed with asthma

• pregnant, breastfeeding, or trying to become pregnant (self-reported)

• medications that, in the opinion of the study physician, may impact the outcomes of the study (e.g., steroids)

• does not own a smartphone or is unwilling to download the required application

Related Conditions & MeSH terms

• Hypertension
• Respiratory Aspiration

Intervention

Behavioral:
• Inspiratory muscle strength training
30 breaths/day against a set resistance

Locations

Country	Name	City	State
United States	Arizona Respiratory and Neurophysiology Laboratory	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
University of Arizona	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline to endpoint 1 (6 weeks) resting systolic blood pressure	Systolic blood pressure (SBP) will be measured by absolute change from baseline. SBP will be assessed in accordance with American College of Cardiology/American Heart Association guidelines. Measurements will be taken using an automated oscillometric sphygmomanometer and will be performed in triplicate over the brachial artery of the left arm after 5 minutes of quiet rest, with 1 minute of recovery between measures. SBP will be defined as the average of the 3 pressures.	Blood pressure will be assessed at baseline and after 6 weeks of training
Primary	Change from endpoint 1 (6 weeks) to endpoint 2 (+12 weeks) resting systolic blood pressure	Systolic blood pressure (SBP) will be measured by absolute change from endpoint 1. SBP will be assessed as described in Outcome 1.	Blood pressure will be assessed after 6 weeks of training and after an additional 12 weeks of training
Primary	Change from baseline to endpoint 1 (6 weeks) Nitric Oxide-mediated Endothelium Dependent Dilation (EDD)	Brachial artery Flow Mediated Dilation (BA-FMD), a well-established measure of NO-mediated endothelial function, will be measured by both relative and absolute changes from baseline. BA-FMD will be determined using high-resolution ultrasonography and analyzed with a commercially available software package. An ultrasound probe will be placed 3-6 cm proximal to the antecubital crease on the right arm and a baseline image of the right brachial artery will be obtained. Following baseline, reactive hyperemia will be produced by inflating a rapid-inflating blood pressure cuff. Brachial artery diameter change will be measured for 2 minutes following 5-min of forearm blood flow occlusion.	EDD will be assessed at baseline and after 6 weeks of training
Primary	Change from endpoint 1 (6 weeks) to endpoint 2 (+12 weeks) Nitric Oxide-mediated Endothelium Dependent Dilation (EDD)	EDD will be assessed as described in Outcome 3	EDD will be assessed after 6 weeks of training and after an additional 12 weeks of training
Secondary	Change from baseline to endpoint 1 (6 weeks) cerebrovascular reactivity (CVR)	CVR will be assessed via changes in middle cerebral artery (MCA) blood velocitywill be assessed in a reclined sitting position while breathing room air and again after 4 min of breathing a medical gas mixture with 5 % CO2 l to elicit vasodilation. A transcranial Doppler probe will be placed over the subject's temple to obtain a velocity tracing from the middle cerebral artery. After a tracing of MCA velocity is obtained and baseline measurements are recorded (while breathing room air), the subject will then switch over to breathing 5% CO2 for	CVR will be assessed at baseline and after 6 weeks of training
Secondary	Change from endpoint 1 (6 weeks) to endpoint 2 (+12 weeks)	CVR will be assessed as described in Outcome 5	CVR will be assessed after 6 weeks of training and after an additional 12 weeks of training